HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 01.wnl.0000192262.29924.9ev1 66/1_suppl_1/S30    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griggs, R. C. Search for Related Content PubMed PubMed Citation Articles by Griggs, R. C.

The current status of treatment for inclusion-body myositis

From the Departments of Neurology, Medicine, Pathology and Laboratory Medicine, and Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY.

Address correspondence and reprint requests to Dr. Robert C. Griggs, Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642; e-mail: Robert_Griggs{at}URMC.Rochester.edu

There is no established treatment that improves, arrests, or slows the progression of inclusion-body myositis (IBM). Many anti-inflammatory, immunosuppressant, or immunomodulating agents have been administered to patients with IBM but the design of clinical trials was such that it can only be concluded that none produced rapid improvement. The natural history of the disease is for stabilization or improvement in a third of patients for 6 months or more. Thus some agents that did not produce dramatic benefit may have been prematurely abandoned. However, because high-dose prednisone worsens strength while decreasing inflammation but increases amyloid accumulation, alternative targets for intervention and novel treatment strategies are needed.

This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.

Disclosure: Dr. Griggs receives support from the NINDS and the Office of Rare Diseases for Clincial Trials in Neuromuscular Diseases.

Received June 22, 2005. Accepted in final form October 14, 2005.

This article has been cited by other articles:

				V. Askanas and W. K. Engel Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48. [Abstract] [Full Text] [PDF]

				W. K. Engel and V. Askanas Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects Neurology, January 24, 2006; 66(1_suppl_1): S20 - S29. [Abstract] [Full Text] [PDF]